Table 3.

Immune profile of the SCID patient from the time of diagnosis up to the age of 7 years^*.

	Result in time points (age in months)
	16	29	Normal range (0–3 yrs)	44	60†	Normal range (3–6 yrs)	77‡	87	Normal range (6–12 yrs)
ALC/mm3	3,753	6,647	3,600–890	3,400	3,355	2,300–5,400	9,255	6,360	1,900–3,700
LYMPHOCYTE SUBPOPULATION [ALC/mm3]
CD19+/B lymphocytes	150	598	720–2,600	884	101	390–1,400	185	191	270–860
CD3+T lymphocytes	1,989	2,061	2,100–6,200	1,054	1,845	1,400–3,700	6,664	4,833	1,200–2,600
CD3+/CD4+ Th lymphocytes	826	465	1,300–3,400	816	336	700–2,200	1,111	700	650–1,500
CD3+/CD8+ Tc lymphocytes	826	997	620–2,000	204	1,007	490–1,300	3,610	2,798	370–1,100
CD3–/CD16+56+ NK Cells	1,576	3,789	180–920	1,360	1,275	130–720	2,314	1,272	100–480

^*Surface markers for flow cytometry contained FITC-labeled CD3, PE-labeled CD16, and CD56, PerCP. Cy^TM5.5-labeled CD45, PE-Cy^TM7-labeled CD4, APC-labeled CD19, and APC-Cy7–labeled CD8. The samples were collected twice and experiments were repeated to rule out the inconsistency in the lymphocyte pattern. To maximize instrument performance and minimize inter-assay variability, CST (Cytometer Set-up and Tracking) beads were run daily on BD Facs-Aria machine. Yrs, years; ALC, absolute lymphocyte count.

^†Lymphocyte count of the last sample collected when the child was shedding VDPV3.

^‡Lymphocyte count of the first sample collected after the child stopped VDPV3 shedding.